PepGen, Sangamo, and Phreesia led premarket losses. PEPG plunged 45% as its trial lacked functional gains. SGMO fell on a wider-than-expected loss, while PHR slumped 27% after slashing its revenue outlook. Despite the poor results, retail sentiment on Stocktwits stayed extremely bullish for all three.